The statistically significant correlation between high stathmin level and poor paclitaxel response according to RECIST criteria in clinical samples and the fact that stathmin level has an independent prognostic value in patients receiving paclitaxel for metastatic disease, not present in patients who do not, in survival analyses, supports the likelihood that the level of stathmin level may act not only as a prognostic marker but also as a predictive marker for response to paclitaxel treatment in endometrial carcinomas. The gene discussed is STMN1; the disease is metastatic neoplasm.